Compare Kyndryl Holdings Inc (KD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs ResMed Inc. — how do they compare? Kyndryl Holdings Inc trades at $11.69 (market cap $2.59B), while ResMed Inc. trades at $230.43 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 12.3× Kyndryl Holdings Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and ResMed Inc. for 51 Days on average.
| KD | RMD | |
|---|---|---|
Market Cap | $2.59B | $31.89B |
Volume | 5,354,348 | 618,314 |
Sector | Technology | Health |
52-Week High | $29.76 | $277.88 |
52-Week Low | $10.59 | $182.82 |
Typical Hold Time | 36 Days | 51 Days |
Enterprise Value | $5.41B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $11.67, up 1.92% today, with a bearish technical signal and neutral oscillators. The company reported a return to profitability in 2025 with net income of $252 million, though revenue has declined from $18.3B in 2022 to $15.1B. Recent news highlights a strategic focus on AI, including a new innovation lab and acquisitions, aiming to drive future growth amid competitive pressures.
The outlook is mixed: positive cash flow and low EV/EBITDA suggest value, but declining revenue and modest analyst consensus ($14.67 target) indicate caution. Key risks include execution on AI initiatives and sustained top-line pressure. Institutional sentiment is neutral with 71% hold ratings, reflecting a wait-and-see approach amid transformation efforts.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
